{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-041889","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2023-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.351481+00:00","generated_at":"2026-06-11T15:04:29.044948+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Revelation Biosciences Q2 2023 net loss $1.4M; cash $15.7M; 6-month net income $4.7M on warrant gain","bullets":["Cash and cash equivalents of $15.7M as of June 30, 2023, up from $5.3M at Dec 31, 2022.","Net loss for Q2 2023 was $1.4M ($0.25 per share) vs $1.8M ($4.16 per share) in Q2 2022.","Net income for 6 months ended June 30, 2023 was $4.7M ($1.61 basic EPS) vs net loss of $8.5M in prior period, driven by $8.2M warrant liability gain.","Net cash used for operating activities for 6 months ended June 30, 2023 was $3.6M, down from $8.5M year-over-year.","Management believes current cash sufficient to fund operations through June 2024; decreased clinical study expenses contributed to lower losses."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-041889","json":"https://secwatch.observer/filing/0000950170-23-041889.json","markdown":"https://secwatch.observer/filing/0000950170-23-041889.md","text":"https://secwatch.observer/filing/0000950170-23-041889.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000095017023041889/0000950170-23-041889-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000095017023041889/revb-20230811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T15:04:29.044948+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fd4982dd29a8a6e461050ac748095d76139ce416","claim":"REVELATION BIOSCIENCES, INC. reported the three and six months ended June 30, 2023 results: net income net loss of $1.4 million, or $0.25 basic and diluted net loss per share, EPS $0.25 basic and diluted net loss per share.","evidence_excerpt":"On August 11, 2023, Revelation Biosciences, Inc. issued a press release announcing its financial results for the three and six months ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000095017023041889/0000950170-23-041889-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and six months ended June 30, 2023"},{"label":"Net income","value":"net loss of $1.4 million, or $0.25 basic and diluted net loss per share"},{"label":"EPS","value":"$0.25 basic and diluted net loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}